These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34976841)

  • 21. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects.
    D'Alessio A; Rimassa L; Cortellini A; Pinato DJ
    J Hepatocell Carcinoma; 2021; 8():887-897. PubMed ID: 34386437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on atezolizumab for hepatocellular carcinoma.
    Ielasi L; Sansone V; Forgione A; Granito A; Benevento F; Tovoli F
    Drugs Today (Barc); 2021 Jun; 57(6):365-375. PubMed ID: 34151903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report.
    Bian LF; Zheng C; Shi XL
    World J Clin Cases; 2021 Jun; 9(16):4110-4115. PubMed ID: 34141773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance.
    Pelizzaro F; Farinati F; Trevisani F
    Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing?
    Cammarota A; Zanuso V; Manfredi GF; Murphy R; Pinato DJ; Rimassa L
    Ther Adv Med Oncol; 2023; 15():17588359221148029. PubMed ID: 36643654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
    J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
    Chan LL; Chan SL
    Expert Opin Emerg Drugs; 2021 Mar; 26(1):39-52. PubMed ID: 33724135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma.
    Wang C; Wei F; Sun X; Qiu W; Yu Y; Sun D; Zhi Y; Li J; Fan Z; Lv G; Wang G
    Front Oncol; 2024; 14():1429919. PubMed ID: 38993637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma.
    Peng X; Gong C; Zhang W; Zhou A
    Front Oncol; 2022; 12():1091088. PubMed ID: 36727075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
    Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
    Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.
    Kang SM; Khalil L; El-Rayes BF; Akce M
    Front Oncol; 2022; 12():821903. PubMed ID: 35433430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma.
    Chan LL; Chan SL
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives.
    Girardi DM; Sousa LP; Miranda TA; Haum FNC; Pereira GCB; Pereira AAL
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies.
    Roderburg C; Özdirik B; Wree A; Demir M; Tacke F
    Hepat Oncol; 2020 May; 7(2):HEP20. PubMed ID: 32647565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.